• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by TELA Bio Inc.

    11/14/25 2:12:33 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care
    Get the next $TELA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    TELA Bio, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    872381108

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    872381108


    1Names of Reporting Persons

    Lytton, Laurence W.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,865,305.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,865,305.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,865,305.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.2 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  The percentages reported in this Schedule 13G are based on 39,616,440 shares of Common Stock outstanding as of August 4, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    TELA Bio, Inc.
    (b)Address of issuer's principal executive offices:

    1 Great Valley Parkway, Suite 24, Malvern, PA 19355
    Item 2. 
    (a)Name of person filing:

    Laurence W. Lytton
    (b)Address or principal business office or, if none, residence:

    467 Central Park West New York, NY 10025
    (c)Citizenship:

    United States
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    872381108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    2,865,305
    (b)Percent of class:

    7.2%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    2,865,305

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    2,865,305

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Lytton, Laurence W.
     
    Signature:/s/ Laurence W. Lytton
    Name/Title:Reporting Person
    Date:11/14/2025
    Get the next $TELA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TELA

    DatePrice TargetRatingAnalyst
    3/21/2025$5.00 → $2.00Overweight → Neutral
    Piper Sandler
    5/31/2022$17.00Buy
    Lake Street
    More analyst ratings

    $TELA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TELA Bio downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded TELA Bio from Overweight to Neutral and set a new price target of $2.00 from $5.00 previously

    3/21/25 8:05:03 AM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    Lake Street initiated coverage on TELA Bio with a new price target

    Lake Street initiated coverage of TELA Bio with a rating of Buy and set a new price target of $17.00

    5/31/22 9:13:36 AM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    $TELA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference

    MALVERN, Pa., Nov. 19, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler's 37th Annual Healthcare Conference. TELA's management is scheduled to present at Piper Sandler's 37th Annual Healthcare Conference at 2:30 pm ET on December 3rd, 2025. Interested parties can access the live and archived webcast at ir.telabio.com. About TELA Bio, Inc.TELA Bio, Inc. (NASDAQ:TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritiz

    11/19/25 8:30:00 AM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    MALVERN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of (i) restricted stock units covering 30,200 shares of its common stock to seventeen newly-hired employees and (ii) an option to purchase 25,000 shares of its common stock to one employee, with a grant date of November 10, 2025 (the "Grant Date"). The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individua

    11/17/25 4:05:00 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    TELA Bio Announces Pricing of $13.0 Million Underwritten Registered Direct Offering of Common Stock and Pre-Funded Warrants

    MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the pricing of an underwritten registered direct offering of 4,189,000 shares of its common stock at a price of $1.11 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 7,523,000 shares of common stock at an offering price of $1.1099 per pre-funded warrant, which represents the per share offering price for the shares of common stock less the $0.0001 per share exercise price. The gross proceeds to TELA from the offering, before deducting unde

    11/13/25 4:21:42 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    $TELA
    SEC Filings

    View All

    TELA Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - TELA Bio, Inc. (0001561921) (Filer)

    11/14/25 4:38:45 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by TELA Bio Inc.

    424B5 - TELA Bio, Inc. (0001561921) (Filer)

    11/14/25 4:20:56 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by TELA Bio Inc.

    10-Q - TELA Bio, Inc. (0001561921) (Filer)

    11/14/25 4:06:56 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    $TELA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ew Healthcare Partners Fund 2, L.P. bought $4,000,440 worth of shares (3,604,000 units at $1.11), increasing direct ownership by 88% to 7,714,709 units (SEC Form 4)

    4 - TELA Bio, Inc. (0001561921) (Issuer)

    11/17/25 4:26:15 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    COO and CFO Cuca Roberto bought $144,999 worth of shares (64,444 units at $2.25), increasing direct ownership by 71% to 155,388 units (SEC Form 4)

    4 - TELA Bio, Inc. (0001561921) (Issuer)

    10/24/24 4:26:40 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    Chief Technology Officer Talmo Paul bought $50,000 worth of shares (22,222 units at $2.25), increasing direct ownership by 32% to 91,082 units (SEC Form 4)

    4 - TELA Bio, Inc. (0001561921) (Issuer)

    10/24/24 4:25:59 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    $TELA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ew Healthcare Partners Fund 2, L.P. bought $4,000,440 worth of shares (3,604,000 units at $1.11), increasing direct ownership by 88% to 7,714,709 units (SEC Form 4)

    4 - TELA Bio, Inc. (0001561921) (Issuer)

    11/17/25 4:26:15 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    Director Plovanic William J. was granted 11,925 shares (SEC Form 4)

    4 - TELA Bio, Inc. (0001561921) (Issuer)

    11/3/25 4:22:34 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Plovanic William J.

    3 - TELA Bio, Inc. (0001561921) (Issuer)

    11/3/25 4:19:21 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    $TELA
    Leadership Updates

    Live Leadership Updates

    View All

    TELA Bio Appoints William Plovanic to Board of Directors

    MALVERN, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- MALVERN, Pa., November 3, 2025 (GLOBE NEWSWIRE) — TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of William ("Bill") Plovanic, CFA, to its Board of Directors. Mr. Plovanic brings a distinctive combination of capital markets expertise and operational leadership in medical technology. He currently serves as Managing Director, Healthcare Equity Research at Canaccord Genuity. From 2016 to 2021, he held C-level operating and board roles at Obalon Therapeutics, a formerly publicly traded medical device com

    11/3/25 4:05:00 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran

    MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Betty Jo Rocchio, DNP, RN, CRNA, CENP, EBP-C, to its Board of Directors, and the departure of Lisa Colleran, who has stepped down following five years of service on the Board. Dr. Rocchio is a nationally recognized healthcare leader and one of Modern Healthcare's 50 Most Influential Clinical Executives. She brings decades of experience in advancing clinical excellence, workforce innovation, and supply-chain transformation across some of the nation's l

    10/9/25 4:05:00 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    TELA Bio Appoints Jeffrey Blizard as President

    MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Jeffrey Blizard as President of TELA Bio, effective immediately. Mr. Blizard, who has served on TELA Bio's Board of Directors for the past year, brings deep industry experience and proven leadership to this expanded role. "This is an important inflection point for TELA Bio," said Antony Koblish, Co-Founder and Chief Executive Officer of TELA Bio. "As we move into the next phase of our growth trajectory, we believe the addition of Jeff—a highly respected l

    6/2/25 8:30:00 AM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    $TELA
    Financials

    Live finance-specific insights

    View All

    TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing and Upsizing of Credit Facility

    MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Revenue of $20.7 million, a 9% increase from the third quarter of 2024Revised full year 2025 revenue guidance of at least 16% growth over full year 2024 Recent Strategic Highlights Strengthened capital position with a credit facility up to $70.0 million debt with Perceptive AdvisorsExpanded Board capabilities with appointments of Betty Jo Rocchio and Bill PlovanicAccelerated hi

    11/13/25 4:01:00 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    TELA Bio to Announce Third Quarter 2025 Financial Results

    MALVERN, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report third quarter 2025 financial results on Thursday, November 13, 2025. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Third Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes befor

    11/4/25 8:30:00 AM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    TELA Bio Reports Second Quarter 2025 Financial Results

    MALVERN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ended June 30, 2025. Recent Highlights Delivered revenue of $20.2 million in the second quarter 2025, representing growth of 26% over the prior year period and sequential growth of 9% over the first quarter of 2025;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the second quarter, resulting in year-over-year revenue increase for each product of approximately 12% and 53%, respectively;Appointed Jeffrey Bliz

    8/11/25 4:03:00 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    $TELA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by TELA Bio Inc.

    SC 13G/A - TELA Bio, Inc. (0001561921) (Subject)

    11/14/24 1:06:57 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by TELA Bio Inc.

    SC 13G - TELA Bio, Inc. (0001561921) (Subject)

    10/29/24 5:12:40 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by TELA Bio Inc.

    SC 13G/A - TELA Bio, Inc. (0001561921) (Subject)

    10/28/24 4:06:51 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care